Immunocore

Update in progress

IMCR (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Immunocore Holdings plc and its subsidiaries develop immunomodulating medicines for cancer, infectious diseases, and autoimmune conditions across the United States, Europe, and globally. It offers KIMMTRAK for unresectable or metastatic uveal melanoma and has multiple programs, including tebentafusp (Phase 3 for advanced cutaneous melanoma and adjuvant uveal melanoma), brenetafusp (Phase 3 for first-line advanced cutaneous melanoma; Phase 1/2 for other tumors), IMC-R117C, IMC-P115C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI. Founded 1999, HQ in Abingdon, UK.

Company score

Sentiment: 0.31; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.32; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.06; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.11; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.21; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive